Jemma Arakelyan, Chief Executive Officer at The Institute of Cancer and Crisis (ICC) and Medical Advisor at Immune Oncology Research Institute, shared a post on LinkedIn:
“Happy to share our review on carbohydrate-based drug discovery. This work appears in a special issue of the Israel Journal of Chemistry honoring Professor Chi-Huey Wong, a pioneer in the field.
Many thanks to Billy Ng for inviting me to contribute, and thank you to Stephan S. for being my ‘partner in crime’.
We cover the full arc: from synthetic strategies to clinical trials – including antivirals, SGLT2 inhibitors, and cancer vaccines.
To my fellow oncology colleagues: if you’re anything like me, you probably think that the role of sugar is simply to fuel cancer cells. That is far from correct. It wasn’t until after contributing to this review that I realized just how powerful carbohydrates can be as a weapon. In fact, one of the many chemotherapy agents we use every day – gemcitabine – relies on a carbohydrate scaffold.
For any colleague who, like me, has become a bit too focused on treating cancer – this article may offer a fresh perspective. It is also a broad and comprehensive read for anyone interested in drug discovery and medicinal chemistry. I hope you’ll give it a read.”
Title: Carbohydrate-Based Drug Discovery: Synthetic Strategies and Clinical Applications
Authors: Stephan Scheeff, Jemma Arakelyan, Billy Wai-Lung Ng.
Other articles featuring Jemma Arakelyan on OncoDaily.